AcquisitionOther
Esperion acquired Corstasis Therapeutics Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Esperion -> Corstasis Therapeutics Inc. · $75 million upfront plus up to $180 million in milestone payments
Brings Enbumyst (nasal spray loop diuretic) to expand cardiovascular product portfolio and accelerate double-digit revenue growth.
Open source record (SEC) ↗